SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for BYSANTI, a new chemical entity with patent protection until 2044 for treating bipolar I disorder and schizophrenia. The community is actively debating the stock's significant undervaluation given this second recent approval, speculating on a potential buyout by larger pharmaceutical companies.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following recent exceptional Phase 2 clinical trial results for its lead drug in axial spondyloarthritis, demonstrating strong efficacy and potential disease-modifying effects. The community is highly bullish, anticipating further positive updates at an upcoming investor day and widely discussing the stock's significant undervaluation amid perceptions of market manipulation.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike faces a sharp sell-off across the cybersecurity sector, driven by market fears that Anthropic's new AI code security tool will disrupt traditional offerings. The community is fiercely debating whether this is an irrational overreaction, with many highlighting CRWD's distinct endpoint and cloud security services and arguing that AI-driven threats will actually increase demand for established cybersecurity leaders.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as reports surface of unsolicited takeover interest from rivals, some eyeing the entire company while others target specific assets like Venmo or Braintree following its significant stock slump. The community is actively debating potential buyers and buyout prices, largely driven by the belief that the fintech giant is fundamentally undervalued given its substantial free cash flow and ongoing share buyback program.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF ($IGV) is experiencing a significant sell-off and hitting new lows, fueled by widespread community fear that Anthropic's Claude AI tools will disrupt and replace traditional software. This "SaaS-pocalypse" is sparking intense debate among investors over whether the market's aggressive reaction is an overblown narrative or a fundamental threat.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit (INTU) is a hot topic as it experiences a dramatic sell-off, with its stock plummeting due to widespread market fears that generative AI will significantly disrupt its core tax and accounting software businesses. Community discussion, however, is sharply divided, with many viewing the heavily oversold conditions as a prime buying opportunity, believing AI will enhance rather than replace Intuit's strong ecosystem ahead of its upcoming earnings.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is facing intense selling pressure, hitting new lows, as the cybersecurity sector grapples with fears that AI tools like Anthropic's Claude Code Security could disrupt existing solutions, prompting community debate between panic selling and 'buy the dip' opportunities ahead of its earnings report.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

The community is fiercely debating Avalanche's substantial price drop to multi-year lows, driven by upcoming token unlocks and the disappointing lack of initial inflows for its recently launched ETF. This deep bearish sentiment persists despite its strong underlying fundamentals and institutional traction in real-world asset tokenization, exacerbated by broader crypto market volatility and regulatory uncertainty.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as it hits new all-time lows following news of a 12% workforce layoff, intensifying community speculation about its financial viability, potential for bankruptcy, and future dilution amidst a challenging EV market.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is surging after Novo Nordisk's weight-loss drug CagriSema underperformed Eli Lilly's tirzepatide, intensifying speculation that Viking's VK2735, a dual GLP-1/GIP agonist with strong tolerability, is now an even more critical acquisition target for major pharma amid a significant short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Attached is our updated tracker of what&#39;s happened to the share prices of all 170 new commercial-stage non-oncology focused bios since receiving FDA approval, going back to 1/1/13. 
 
Since we last published, $DVAX announced it was being acquired. As of Friday&#39;s close, DVAX&#39;s share price is off 13% since receiving FDA approval. 
 
$FOLD announced it was being acquired for $14.50 per share, reflecting roughly a 3% increase since its closing share price as of Galafold&#39;s 1st approval. 
 
Unlike oncology, there are a few non-oncology focused bios that have gone on to deliver meaningful gains to shareholders post FDA approval. $VCEL $INSM &amp; $LQDA share prices are up 800 to 1,000% since their 1st products were approved. 
 
Otherwise, the evidence is overwhelming shareholder value is maximized via sale within 3 years of FDA approval (versus 2 years in oncology) just under 90% of the time. 
 
As always, we may have missed a stock split (especially in those trading lower).  
 
This is not investment advice.

Bryan

Tony Tony

Victor

Robert Melis

$MNKD Q: Why is $LQDA up 800-1000% but but MannKind is mired at $1.25 pre-split? A: Leadership matters. #FireMike

StockTwits for iOS

Abraham Ben Yiju

StockTwits Web

Dynavax Technologies Corp.

Amicus Therapeutics Inc

Vericel Corp

Insmed Inc

Liquidia Corp

Attached is our updated tracker of what's happened to the share prices of all 170 new commercial-stage non-oncology focused bios since receiving FDA approval, going back to 1/1/13. 
 
Since we last published, 

 announced it was being acquired. As of Friday's close, DVAX's share price is off 13% since receiving FDA approval. 
 


 announced it was being acquired for $14.50 per share, reflecting roughly a 3% increase since its closing share price as of Galafold's 1st approval. 
 
Unlike oncology, there are a few non-oncology focused bios that have gone on to deliver meaningful gains to shareholders post FDA approval. 

 share prices are up 800 to 1,000% since their 1st products were approved. 
 
Otherwise, the evidence is overwhelming shareholder value is maximized via sale within 3 years of FDA approval (versus 2 years in oncology) just under 90% of the time. 
 
As always, we may have missed a stock split (especially in those trading lower).  
 
This is not investment advice.